ArticleAfrican journal of laboratory medicine2022
GeneXpert rollout in three high-burden tuberculosis countries in Africa: A review of pulmonary tuberculosis diagnosis and outcomes from 2001 to 2019.
Article in African journal of laboratory medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Impact of antenatal screening for Chlamydia and Gonorrhea on pregnancy outcomes in South African women.BMC infectious diseases · 2026Article
- A retrospective analysis of tuberculosis notification trends and spatial distribution in South Africa, 2005-2012.Discover public health · 2026Article
- Article
- Predisposing, enabling, and need factors influencing rapid uptake of the world health organization-endorsed TB diagnostic technologies in Africa.BMC infectious diseases · 2025Article
- Rifampicin-resistantJournal of clinical tuberculosis and other mycobacterial diseases · 2025Article
- Performance of CAD4TB artificial intelligence technology in TB screening programmes among the adult population in South Africa and Lesotho.Journal of clinical tuberculosis and other mycobacterial diseases · 2025Article
- Access to tuberculosis care in South Africa during the COVID-19 pandemic: A scoping review.African journal of primary health care & family medicine · 2025Article
- Survey of clinical microbiology and infectious disease testing capabilities among institutions in Africa.American journal of clinical pathology · 2025Article
- The burden of tuberculosis and drug resistance in 22 Sub-Saharan African countries, 1990-2021: a GBD 2021 analysis and progress towards WHO 2035 targets with projections to 2050.Frontiers in microbiology · 2025Article
- Study protocol: a pragmatic, cluster-randomized controlled trial to evaluate the effect of implementation of the Truenat platform/MTB assays at primary health care clinics in Mozambique and Tanzania (TB-CAPT CORE).BMC infectious diseases · 2024Article
- Xpert MTB/RIF Ultra on contaminated liquid cultures for tuberculosis and rifampicin-resistance detection: a diagnostic accuracy evaluation.The Lancet. Microbe · 2023Article
- What clinic closure reveals about care for drug-resistant TB: a qualitative study.BMC infectious diseases · 2023Article
- Quality Assurance for Hepatitis C Virus Point-of-Care Diagnostics in Sub-Saharan Africa.Diagnostics (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Background: The rollout of GeneXpert aimed at increasing early diagnosis of tuberculosis to improve treatment outcomes and global tuberculosis targets. Objective: This study evaluated trends in tuberculosis diagnosis and outcomes pre- and post-introduction of GeneXpert in three African countries - the Democratic Republic of the Congo (DRC), Nigeria and South Africa. Methods: Data from 2001 to 2019 were extracted from the World Health Organization's data repository. Descriptive analysis, paired Results: Estimated tuberculosis incidence decreased from 327/100 000 to 324/100 000 in the DRC, and from 1220/100 000 to 988/100 000 in South Africa. Incidence remained at 219/100 000 in Nigeria. The tuberculosis case notification rate did not change significantly. Increases in the new case treatment success rates were statistically significant (DRC: Conclusion: Improvements in tuberculosis treatment outcomes were achieved, but little progress has been made in new case notification due to varied implementation and scale-up of GeneXpert across the three countries. Implementation barriers need to be addressed to achieve the required tuberculosis targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.